Supported by:	Media Partner:

PRELIMINARY PROGRAMME

*** REGISTER NOW AS A GUEST (UCL staff and students, UCL guests, speakers) ***

*** REGISTER NOW AS A PAYING PARTICIPANT (GBP199 / EUR252) ***

New technologies will force fundamental change in the way healthcare systems operate. Low-cost gene sequencing and biopharmaceuticals will make personalised medicine a reality – tailoring the treatment to the patient.

The spread of broadband networks makes telemedicine feasible for many, and computerised patient records will transform medical research. New imaging and diagnostics technologies open the door to more preventative medicine.

So what will it be like to be sick in 2020? Who will treat you? How will they get paid? How will health authorities decide which new technologies are worth the money?

These are among the pressing questions to be examined at an international gathering at UCL, London, of research, industry and policy experts on 5/6 November, organised by UCL Advances, University College London’s centre for entrepreneurship and business interaction, and the Science|Business news service.

The Agenda

5 November: 19:30 - 22:00. Executive Forum – a by- invitation roundtable discussion among speakers and selected guests, to map out scenarios of the future together – and make recommendations for policy action. The result will be a special report of the Forum’s work by Science|Business, for presentation at the next day’s public conference.
Followed by dinner, chaired by a senior UCL representative.

6 November: 9:00 - 16:00. Conference. Presentations by selected stakeholders from research, industry, investment and policy, and open discussion, in plenary sessions and break-out groups. (People wishing to present are invited to contact Richard L. Hudson, editor of Science|Business.)

Themes for discussion

• In the doctor’s office – the new diagnostics and personalised medicine.
• In the hospital – telemedicine, imaging, operating theatres.
• In the healthcare system – electronic patient records, treatment approvals, financing mechanisms.
• Investment focus &ndahs; expert discussion of how converging technologies will change the healthcare industry, and investment opportunities.
• Policy focus – expert discussion of how converging technologies will change the administration and policy of healthcare. Includes presentation of Executive Forum policy recommendations from the day before.

Speaking:

• Graham Spittle, Chairman, UK Technology Strategy Board
• Prof. Malcolm Grant, President and Provost, UCL
• Erik Tambuyzer, Senior Vice President, Genzyme
• Georgette Lilas, Director for Consumer Goods, European Commission
• Mark Britnell, Director-General for Commissioning, UK Department of Health
• Hermann Hauser, Chairman, Amadeus Capital Partners
• Stephan Mumenthaler, Head of Economic Affairs, Novartis
• Niall Dickson, CEO, King’s Fund
• Alain Parthoens, Partner, Vesalius BioCapital and President, Belgian Venture Capital and Private Equity Association
• Gerhard Engel, Head of R&D, Accelrys UK
• Prof. Mike Spyer, Vice-Provost(Enterprise), UCL
• Prof. Ed Byrne, UCL
• Prof. John Martin, UCL
• ...and more

Who will attend

• Decision makers in corporate R&D, business development and public affairs
• Leading-edge researchers from business and academia
• Not-for-profit research funders
• Policy and decision makers in public health andgovernment
• Life-science investors

For more information, contact richard.hudson@sciencebusiness.net

PRELIMINARY PROGRAMME

*** REGISTER NOW ***